Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-06-07
2010-10-19
Russel, Jeffrey E (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S937000
Reexamination Certificate
active
07816318
ABSTRACT:
Disclosed are compositions and methods for treating a patient with a pharmaceutically active agent other than insulin selected from the group consisting of peptides, peptidomimetics, and proteins, wherein the pharmaceutical composition is in the form of an emulsified nasal spray comprising: a macrocyclic permeation enhancer, a liquid carrier comprising water, and a therapeutically effective amount of the pharmaceutically active agent; wherein the macrocyclic permeation enhancer is a Hsieh enhancer emulsified in the liquid carrier; and wherein the Hsieh enhancer has the following structure:wherein X and Y are oxygen, sulfur or an imino group of the structureor ═N—R with the proviso that when Y is the imino group, X is an imino group, and when Y is sulfur, X is sulfur or an imino group; A is a group having the structureand the remaining variables are defined herein.
REFERENCES:
patent: 5118676 (1992-06-01), Minaskanian
patent: 5196410 (1993-03-01), Francoeur
patent: 5902789 (1999-05-01), Stoltz
patent: 5989535 (1999-11-01), Nayak
patent: 6143778 (2000-11-01), Gautier et al.
patent: 7244703 (2007-07-01), Gyurik et al.
patent: 0272097 (1988-06-01), None
patent: 1158017 (1989-06-01), None
patent: 8502092 (1985-05-01), None
patent: 8703473 (1987-06-01), None
patent: WO 03/000158 (2003-01-01), None
patent: 03028702 (2003-04-01), None
Mitra et al. “Lipid emulsions as vehicles for enhanced nasal delivery of insulin” International Journal of Pharmaceutics (Kidlington), vol. 205, No. 1-2 (2000), p. 127-134.
Takala et al. “Pharmacokinetic comparison of intravenous and intranasal administration of oxycodone” ACTA Anaesthesiologica Scandinavica, vol. 41, No. 2, 1997, p. 309-312.
Drejer et al. “Intranasal Administration of Insulin With Phospholipid as Absorption Enhancer: Pharmacokinetics in Normal Subjects,” Diabetic Medicine, 1992, pp. 335-340.
Hinchcliffe et al. “Intranasal insulin delivery and therapy,” Advanced Drug Delivery Reviews, 1999, vol. 35, pp. 199-234.
International Search Report for the International Application No. PCT/US02/19849 issued by the International Searching Authority mailed on Oct. 18, 2002.
International Preliminary Examination Report for the International Application No. PCT/US02/19849 issued by the International Preliminary Examining Authority mailed on Dec. 10, 2003.
International Search Report for the International Application No. PCT/US05/07449 issued by the International Searching Authority mailed on Nov. 1, 2005.
Written Opinion for the International Application No. PCT/US05/07449 issued by the International Searching Authority mailed on Nov. 1, 2005.
Gyurik Robert J.
Reppucci Carl
CPEX Pharmaceuticals, Inc.
Davitz Michael A.
Russel Jeffrey E
LandOfFree
Pharmaceutical compositions and methods for peptide treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions and methods for peptide treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions and methods for peptide treatment will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4171146